AU2008327792B2 - Peptides that can bind to scurfin and uses thereof - Google Patents

Peptides that can bind to scurfin and uses thereof Download PDF

Info

Publication number
AU2008327792B2
AU2008327792B2 AU2008327792A AU2008327792A AU2008327792B2 AU 2008327792 B2 AU2008327792 B2 AU 2008327792B2 AU 2008327792 A AU2008327792 A AU 2008327792A AU 2008327792 A AU2008327792 A AU 2008327792A AU 2008327792 B2 AU2008327792 B2 AU 2008327792B2
Authority
AU
Australia
Prior art keywords
peptide
seq
scurfin
phe
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008327792A
Other languages
English (en)
Other versions
AU2008327792A1 (en
Inventor
Francisco Borras Cuesta
Ines Noelia Casares Lagar
Juan Jose Lasarte Sagastibelza
Jesus Prieto Valtuena
Pablo Sarobe Ugarriza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Publication of AU2008327792A1 publication Critical patent/AU2008327792A1/en
Application granted granted Critical
Publication of AU2008327792B2 publication Critical patent/AU2008327792B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2008327792A 2007-11-19 2008-11-14 Peptides that can bind to scurfin and uses thereof Ceased AU2008327792B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200703052 2007-11-19
ES200703052A ES2328776B1 (es) 2007-11-19 2007-11-19 Peptidos con capacidad para unirse a escurfina y aplicaciones.
PCT/ES2008/000716 WO2009065982A1 (es) 2007-11-19 2008-11-14 Péptidos con capacidad para unirse a escurfina y aplicaciones

Publications (2)

Publication Number Publication Date
AU2008327792A1 AU2008327792A1 (en) 2009-05-28
AU2008327792B2 true AU2008327792B2 (en) 2014-04-24

Family

ID=40409793

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008327792A Ceased AU2008327792B2 (en) 2007-11-19 2008-11-14 Peptides that can bind to scurfin and uses thereof

Country Status (11)

Country Link
US (1) US8524860B2 (OSRAM)
EP (1) EP2223998B1 (OSRAM)
JP (1) JP5385910B2 (OSRAM)
CN (1) CN101903514B (OSRAM)
AU (1) AU2008327792B2 (OSRAM)
BR (1) BRPI0819311A2 (OSRAM)
CA (1) CA2706201A1 (OSRAM)
ES (1) ES2328776B1 (OSRAM)
MX (1) MX2010005520A (OSRAM)
RU (1) RU2502741C2 (OSRAM)
WO (1) WO2009065982A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
CA2765171C (en) 2009-06-10 2018-10-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
US10196608B2 (en) * 2014-02-21 2019-02-05 Cellectis Method for in situ inhibition of regulatory T cells
ES2665543B1 (es) 2016-10-26 2019-02-12 Fundacion Para La Investig Medica Aplicada Péptidos de unión a FOXP3 y usos de los mismos

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102640A1 (en) * 2000-02-09 2002-08-01 Hubert Rene S. 83P5G4: a tissue specific protein highly expressed in prostate cancer
US20060002993A1 (en) * 2001-11-07 2006-01-05 Challita-Eid Pia M Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2007084775A2 (en) * 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698015A (en) * 1995-05-19 1997-12-16 Nikko Company Conductor paste for plugging through-holes in ceramic circuit boards and a ceramic circuit board having this conductor paste
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
AU5559499A (en) * 1998-08-11 2000-03-06 Darwin Discovery Limited Identification of the gene causing the mouse scurfy phenotype and its human ortholog
ATE405586T1 (de) * 2001-05-08 2008-09-15 Darwin Molecular Corp Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
US20080085261A1 (en) * 2004-10-19 2008-04-10 Haynes Barton F Vaccine Adjuvant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102640A1 (en) * 2000-02-09 2002-08-01 Hubert Rene S. 83P5G4: a tissue specific protein highly expressed in prostate cancer
US20060002993A1 (en) * 2001-11-07 2006-01-05 Challita-Eid Pia M Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2007084775A2 (en) * 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation

Also Published As

Publication number Publication date
RU2502741C2 (ru) 2013-12-27
US8524860B2 (en) 2013-09-03
ES2328776B1 (es) 2010-07-06
RU2010125199A (ru) 2011-12-27
JP5385910B2 (ja) 2014-01-08
BRPI0819311A2 (pt) 2015-06-16
CN101903514A (zh) 2010-12-01
EP2223998B1 (en) 2015-05-13
US20100267623A1 (en) 2010-10-21
EP2223998A1 (en) 2010-09-01
AU2008327792A1 (en) 2009-05-28
JP2011504108A (ja) 2011-02-03
CN101903514B (zh) 2013-07-17
ES2328776A1 (es) 2009-11-17
CA2706201A1 (en) 2009-05-28
MX2010005520A (es) 2010-09-28
WO2009065982A1 (es) 2009-05-28

Similar Documents

Publication Publication Date Title
US8524860B2 (en) Peptides with capacity to bind to scurfin and applications
CN101679488A (zh) 能与白介素-10(il-10)结合的肽
JP4299777B2 (ja) 免疫応答を誘導するための方法および組成物
Mukai et al. Creation of novel Protein Transduction Domain (PTD) mutants by a phage display-based high-throughput screening system
US11384119B2 (en) Compositions and methods for inhibiting CD279 interactions
CN111925413B (zh) Koc1衍生的肽和包含它们的疫苗
JP2022191303A (ja) Ｆｏｘｐ３結合ペプチド及びその使用
ES2395336T3 (es) Métodos y moléculas inmunoterapéuticos
WO2024077376A1 (en) Novel tumor-specific antigens for myeloid leukemia and uses thereof
US20230257429A1 (en) Peptide adjuvant for its therapeutic applications in viral and tumour vaccine development and cancer immunotherapy and autoimmune disease diagnosis and treatments
US20260130976A1 (en) Novel tumor-specific antigens for myeloid leukemia and uses thereof
WO2024108303A1 (en) Novel tumor-specific antigens for lymphoid leukemia and uses thereof
HK1256884B (en) Compositions and methods for inhibiting cd279 interactions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired